Evidence map›Paper›PMID 26585412›Full record

Trial reportLeukemia2016

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

D A Eichenauer, H Goergen, A Plütschow, D Wongso, K Behringer, S Kreissl, I Thielen, T Halbsguth, P J Bröckelmann, M Fuchs and 4 more

Abstract readClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.Hematology. American Society of Hematology. Education Program · 2017
    Review
  10. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.Current hematologic malignancy reports · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

D A EichenauerDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
H GoergenDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
A PlütschowDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
D WongsoGerman Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
K BehringerDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
S KreisslDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
I ThielenGerman Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
T HalbsguthGerman Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
P J BröckelmannDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
M FuchsDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
B BöllDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
B von TresckowDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
P BorchmannDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.
A EngertDepartment of Internal Medicine, University Hospital Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsFemaleGermanyHodgkin DiseaseHumansMaleMiddle AgedRecurrenceSalvage TherapySurvival RateYoung AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agentsofatumumab

Identifiers

PMID26585412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.